VANGUARD GROUP INC - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 63 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$6,324,797
-25.0%
4,902,9430.0%0.00%
Q2 2023$8,433,062
+13.6%
4,902,943
-0.2%
0.00%
Q1 2023$7,421,730
+1.2%
4,915,053
+7.2%
0.00%
Q4 2022$7,337,154
+11.5%
4,585,721
+1.1%
0.00%
Q3 2022$6,580,000
-29.2%
4,537,961
-10.6%
0.00%
Q2 2022$9,294,000
-33.4%
5,078,387
-2.8%
0.00%
Q1 2022$13,945,000
-37.0%
5,222,886
+2.2%
0.00%
-100.0%
Q4 2021$22,118,000
-21.2%
5,107,991
-7.4%
0.00%0.0%
Q3 2021$28,078,000
-17.2%
5,516,321
+3.0%
0.00%0.0%
Q2 2021$33,917,000
-5.9%
5,358,085
+15.0%
0.00%0.0%
Q1 2021$36,027,000
+87.4%
4,660,798
+58.8%
0.00%0.0%
Q4 2020$19,221,000
+1.3%
2,934,424
+2.8%
0.00%0.0%
Q3 2020$18,980,000
-14.1%
2,854,188
+7.6%
0.00%0.0%
Q2 2020$22,093,000
+6.3%
2,652,335
-2.1%
0.00%0.0%
Q1 2020$20,789,000
-7.0%
2,710,539
+0.8%
0.00%0.0%
Q4 2019$22,350,000
+16.1%
2,689,604
+3.1%
0.00%0.0%
Q3 2019$19,258,000
-35.7%
2,609,498
-2.3%
0.00%0.0%
Q2 2019$29,973,000
+15.6%
2,671,374
+10.8%
0.00%0.0%
Q1 2019$25,929,000
+17.9%
2,412,019
+65.7%
0.00%0.0%
Q4 2018$21,985,000
-52.6%
1,455,924
-41.9%
0.00%
-50.0%
Q3 2018$46,343,000
-4.2%
2,504,987
+18.3%
0.00%0.0%
Q2 2018$48,400,000
+16.2%
2,117,265
+44.6%
0.00%0.0%
Q1 2018$41,648,000
+64.3%
1,463,883
+21.9%
0.00%
+100.0%
Q4 2017$25,355,000
+21.5%
1,201,111
+4.6%
0.00%0.0%
Q3 2017$20,864,000
+45.7%
1,148,206
+24.2%
0.00%0.0%
Q2 2017$14,323,000
+0.7%
924,138
+12.2%
0.00%0.0%
Q1 2017$14,223,000
+62.6%
823,531
+3.5%
0.00%
Q4 2016$8,748,000
-28.9%
795,999
+1.4%
0.00%
-100.0%
Q3 2016$12,303,000
+224.2%
784,646
+111.2%
0.00%
Q2 2016$3,795,000
+27.9%
371,522
+61.5%
0.00%
Q1 2016$2,968,000
-28.6%
230,056
+15.5%
0.00%
Q4 2015$4,156,000199,1370.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 524,763$7,924,0003.84%
Congress Park Capital LLC 123,311$1,862,0002.05%
Perceptive Advisors 2,911,715$43,588,0001.66%
RTW INVESTMENTS, LP 908,586$13,720,0001.28%
HAMILTON LANE ADVISORS LLC 68,753$1,038,0000.91%
HARBOURVEST PARTNERS LLC 79,193$1,196,0000.57%
SPHERA FUNDS MANAGEMENT LTD. 273,151$4,125,0000.46%
Exane Asset Management 50,000$755,000,0000.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 622,548$9,400,0000.38%
Cormorant Asset Management, LP 296,712$4,480,0000.36%
View complete list of CYTOMX THERAPEUTICS INC shareholders